U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096609) titled 'Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients' on July 24.
Brief Summary: The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
Study Start Date: Sept. 08
Study Type: INTERVENTIONAL
Condition:
GIST
Intervention:
DRUG: Lenvatinib Capsules
Lenvatinib will be administered orally once daily at a dose of 12 mg (for patients weighing >= 60 kg) or 8 mg (for patients weighing < 60 kg). Each treatment cycle consists of 4 weeks (i.e., 28 days).
Recruitment St...